On Mar. 20, 2020, Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response.

Hydroxychloroquine and a related drug, chloroquine, were under evaluation in clinical trials for the treatment of COVID-19. Novartis was supporting ongoing clinical trial efforts, and evaluated needs for additional clinical trials.